BPC-157 vs MK-677
Extensively Studied vs Well Studied
compatible Systemic growth factors complement localized healing.
Molecular Data
BPC-157 MK-677
Weight 1,419.53 Da 624.77 Da
Half-life <30 minutes ~24 hours
Chain 15 amino acids —
Type Pentadecapeptide Non-peptide ghrelin receptor agonist
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
BPC-157 MK-677
Status Extensively Studied Well Studied
References 6 studies 5 studies
Latest January 2025 July 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.